score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline			Copy Number	CDK4	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				CDK4 Amplification	1.0	Osteosarcoma-VMO265	VMO265_T	
Putatively Actionable	Preclinical		Preclinical	Copy Number	AURKA	Amplification				0.0	0.0		Putatively Actionable	Danusertib	Aurora kinase inhibition	Targeted therapy	Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).	Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.	https://doi.org/10.1158/2159-8290.CD-11-0130								Putatively Actionable	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				AURKA Amplification		Osteosarcoma-VMO265	VMO265_T	
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Splice Site		0.0411	73.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf													0	0.0	0.0	0.0	MET  (Splice Site)		Osteosarcoma-VMO265	Osteosarcoma-VMO265-Tumor-SM-2RCBP	Osteosarcoma-VMO265-Normal-SM-2RCD5
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						Osteosarcoma-VMO265		
Investigate Actionability	Preclinical			Copy Number	FGFR2	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR2 Deletion		Osteosarcoma-VMO265	VMO265_T	
Biologically Relevant				Rearrangement	TP53	Fusion	TP53--CDK12			0.0	0.0																					0				TP53--CDK12 Fusion		Osteosarcoma-VMO265		
Biologically Relevant				Rearrangement	CDK12	Fusion	TP53--CDK12			0.0	0.0																					0				TP53--CDK12 Fusion		Osteosarcoma-VMO265		
Biologically Relevant				Rearrangement	TP53	Fusion	TCF7L2--TP53			0.0	0.0																					0				TCF7L2--TP53 Fusion		Osteosarcoma-VMO265		
Biologically Relevant				Copy Number	NF1	Deletion				0.0	0.0																					0				NF1 Deletion		Osteosarcoma-VMO265	VMO265_T	
Biologically Relevant				Copy Number	RAD51D	Deletion				0.0	0.0																					0				RAD51D Deletion		Osteosarcoma-VMO265	VMO265_T	
Biologically Relevant				Copy Number	TACC3	Deletion				0.0	0.0																					0				TACC3 Deletion		Osteosarcoma-VMO265	VMO265_T	
Biologically Relevant				Copy Number	FGFR3	Deletion				0.0	0.0																					0				FGFR3 Deletion		Osteosarcoma-VMO265	VMO265_T	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAA58del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAA58del (Deletion)		Osteosarcoma-VMO265		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.348																									0				COSMIC Signature (version 2) 1 (35%)		Osteosarcoma-VMO265		
Biologically Relevant				Mutational Signature	COSMIC Signature 30	version 2	0.239																									0				COSMIC Signature (version 2) 30 (24%)		Osteosarcoma-VMO265		
